30 June 2011
Limitations of Rituximab/IVIg desensitization protocol in kidney transplantation; Is this better than a tincture of time?Tomasz KozlowskiABCDEF, Kenneth A. AndreoniCDEF
Ann Transplant 2011; 16(2): 19-25 :: ID: 881860
Background: A plasmapheresis-free protocol for desensitization of donor kidney transplant candidates with high Calculated Panel Reactive Antibody (CPRA) was initiated at our center. The protocol was adopted from previously published work by Vo, Jordan et al.
Material/Methods: Five patients with CPRA of 94±18%, awaiting kidney transplant from living or deceased donors received rituximab (1 g × 2 doses) and intravenous immunoglobulin (IVIG 2 g/kg × 2 doses) without plasmapheresis. Levels of donor specific antibodies (DSA) and T/B cell crossmatches were followed using solid phase flow cytometry.
Results: Three out of 5 patients were sensitized only to Class II HLA antigens. All patients had very high levels of alloantibodies before initiation of the treatment. All of the candidates initially demonstrated reduced levels of HLA antibody, but statistical significance was only obtained in one patient Class II antibody and in another only for Class I. Depletion was transient with observed antibody rebound. Rituximab effectively depleted CD20 cells in peripheral blood. None of the patients were transplanted due to persistently high levels of antibody and strong positive flow cytometry crossmatches. Under this protocol, reduction of HLA antibodies in patients with high levels was insufficient.
Conclusions: Highly allo-sensitized patients with a CPRA above 85% may not benefit from a combination of rituximab-IVIG alone. The previously published protocol does not help all patients achieve an acceptable crossmatch. An individualized approach to the treatment of highly sensitized patients is still required.
Keywords: limitations of desensitization, Kidney, Transplantation, rituximab, IVIG
04 Aug 2022 : Original articleLong-Term Patency of All-in-One Sleeve Patch Graft Venoplasty in 16 Patients Who Underwent Living Donor Liv...
Ann Transplant In Press; DOI: 10.12659/AOT.936888
22 Jul 2022 : Original articleDiagnostic Role of Tumor Markers for Hepatocellular Carcinoma in Liver Transplantation Candidates: An Analy...
Ann Transplant In Press; DOI: 10.12659/AOT.936937
22 Jul 2022 : Original articleDevelopment of a Novel Model for Predicting Postoperative Short-Term Outcome in Patients with Hepatitis B-R...
Ann Transplant In Press; DOI: 10.12659/AOT.936732
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review articleKidney Transplantation in the Times of COVID-19 – A Literature Review
Ann Transplant 2020; 25:e925755